Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Auxilium Pharmaceuticals and Bentley Pharmaceuticals have reported that the US Patent and Trademark Office has issued US patent covering hypogonadism drug Testim, 1% testosterone gel, marketed by Auxilium under license from Bentley.
Subscribe to our email newsletter
The patent will expire in January 2025. Auxilium plans to list the patent promptly in approved drug products with therapeutic equivalence evaluations (commonly known as the Orange Book), published by the FDA. The companies have also announced that Bentley has filed a divisional application and continuations with the USPTO, which, if granted, may expand the scope of patent claims covering Testim.
Armando Anido, CEO and president of Auxilium, said: “We are very pleased that Testim now has patent protection through January 2025. Testim is a great product that continues to take market share and grow at a high rate, so extending our patent protection through January 2025 is an important accomplishment.”